RGEN: Summary for Repligen Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:05am EST - Canadian Markets open in 1 hour and 25 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Repligen Corporation (RGEN)

On Feb 9: 3.40 USD 0.00 (0.00%)

MORE ON RGEN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Repligen Corporation (NGM:RGEN) Delayed quote data

Last Trade:	3.40 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	3.40
Open:	N/A
Bid:	3.02 x 100
Ask:	4.99 x 200
1y Target Est:	9.00

Day's Range:	N/A - N/A
52wk Range:	3.35 - 5.85
Volume:	0
Avg Vol (3m):	121,895
Market Cap:	104.58M
P/E (ttm):	N/A
EPS (ttm):	-0.15
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RGEN to Portfolio

Download Data

HEADLINES

•	3 Stocks Hitting Low Notes
	at Motley Fool (Thu, Feb 4)

•	Repligen Corporation F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
	at Seeking Alpha (Thu, Feb 4)

•	REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
	EDGAR Online (Thu, Feb 4)

•	Repligen Reports Third Quarter Fiscal Year 2010 Financial Results
	PRNewswire (Thu, Feb 4)

•	Q3 2010 Repligen Corporation Earnings Release - Before Market Open
	CCBN (Thu, Feb 4)

•	REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Ag
	EDGAR Online (Wed, Feb 3)

•	Repligen Receives Notice of Allowance for Recombinant Protein A Patent
	PRNewswire (Wed, Feb 3)

•	Repligen to Present at the BIO CEO & Investor Conference Monday, February 8th, 2:00 p.m. EST
	PRNewswire (Mon, Feb 1)

•	Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST
	PRNewswire (Fri, Jan 29)

•	4 Stocks That Laugh at Wall Street
	at Motley Fool (Thu, Jan 28)

More Headlines for RGEN...

ANALYST

EPS Est (next year) (Mar-10) :	-0.15
EPS Est (in 2 years) (Mar-11) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies.

Full Company Profile

Add to Portfolio

Email to a Friend

•